Header
For Healthcare Professionals
Carosel_01_new11

FOR COMPREHENSIVE PROTECTION ACROSS MULTIPLE INDICATIONS,

Make JARDIANCE your go-to first-line choice for CV protection in any of the following conditions:

View Footnotes and references
Carosel_02_new111

JARDIANCE has demonstrated CV protection to a broad range of patients by reducing CV and kidney risk1-4

View footnotes and references
Carosel_03_new1111

IN THE TREATMENT OF PATIENTS WITH HFrEF AND HEpEF*†

Prescribe JARDIANCE as a foundational heart failure treatment to help protect their heart and kidneys across the LVEF spectrum

…by reducing the risk of CV death and HHF and slowing the decline of renal function1-3
View footnotes and references

Heart failure, regardless of rEF or pEF, is a progressive condition that needs urgent, optimal intervention1-4

Early treatment optimisation can help reduce the risk of CV death or hospitalisation

HF-Image-Zoom
HF-Image-Zoom

  • ACM=all-cause mortality; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HF=heart failure; HRQoL=health-related quality of life; pEF=preserved ejection fraction; rEF=reduced ejection fraction.

  1. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476-2486.

  2. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11(1):263-276.

  3. Abdin A, Anker SD, Butler J, et al. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Failure. 2021;8(6):4444-4453.

  4. Maddox TM, Januzzi JL, Allen LA, et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. J Am Coll Cardiol. 2024;83(15):1444-1488.

  5. Nair R, Lak H, Hasan S, Gunasekaran D, Barbar A, Gopalakrishna KV. Reducing all-cause 30-day hospital readmissions for patients presenting with acute heart failure exacerbations: a quality improvement initiative. Cureus. 2020;12(3):e7420.

  6. Bytyçi I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015;15(1):63-68.

  7. Sepehrvand N, Savu A, Spertus JA, et al; Alberta HEART Investigators. Change of health-related quality of life over time and its association with patient outcomes in patients with heart failure. J Am Heart Assoc. 2020;9(17):e017278.

  8. House AA, Wanner C, Sarnak MJ, et al; Conference Participants. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(6):1304-1317.

Unmet needs: According to national heart failure registry1

For patients who get hospitalized for an acute decompensated heart-failure:

  • Nearly 1 out of every 7 such patients will die within 90-days of initial hospital admission

  • Nearly 1 out of every 12 such patients will require a re-hospitalization within 90-days of initial hospital admission.

  • Initiation of guideline-directed medical therapy at hospital-discharge, results in significantly improved clinical outcomes over 90-days

HF-graph-image-fig-1

NHFR data

 

  • 10 851 ADHF patients

  • 53 centres across 21 states

     

Key findings

 

  • GDMT for HFrEF = 47.5%

  • GDMT for HFmrEF = >33.3%

  • In-hospital mortality = 6.7%

  • ADHF=acute decompensated heart failure; GDMT=guideline-directed medical therapy; HFmrEF=heart failure with mildly reduced ejection fraction; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction.

  1. Harikrishnan S, Bahl A, Roy A, et al. NHFR Investigators. Clinical profile and 90 day outcomes of 10851 heart failure patients across India: National Heart Failure Registry. ESC Heart Fail. 2022;9(6):3898-3908.

Findings call for innovative quality improvement initiatives to improve the uptake of GDMT in our HF patients